PD-1 antibody cemiplimab demonstrates 46.3% ORR in advanced cutaneous squamous cell carcinoma

FDA clears the way for multi-center investigator-initiated study of Alpha DaRT in immunocompromised patients with recurrent cSCC

FDA approved an Investigational Device Exemption application to initiate a multi-center study for the treatment of recurrent cutaneous squamous cell carcinoma in immunocompromised patients using the Alpha DaRT.

October 11, 2024

Vol.50 No.38

Annual Report to the Nation: Declines in lung cancer, melanoma death rates drive overall cancer mortality drop

From 2015 to 2018, the overall cancer death rate in the United States fell by 2.3% per year for men and 2.1% per year for women—an unprecedented drop, led by accelerated decline in deaths from lung cancer and melanoma.

July 09, 2021

Vol.47 No.27

By Alexandria Carolan

Clinical

Cleveland Clinic study: timing of melanoma diagnosis, treatment critical to survival

A new Cleveland Clinic study underscores the importance of early detection and treatment of melanoma, the deadliest form of skin cancer.

November 07, 2017

Vol.40 No.09

Clinical

Delaying lymph node biopsy after diagnosis doesn’t affect survival

Postponing lymph node biopsy more than 30 days after melanoma diagnosis doesn't adversely impact long-term clinical outcomes, according to new study findings published online as an “article in press” on the Journal of the American College of Surgeons website ahead of print publication.

August 03, 2017

Vol.40 No.07

Clinical

Part 2 of phase III study of binimetinib and encorafenib produces positive top-line result

Array BioPharma announced top-line results from part 2 of the phase III COLUMBUS study evaluating binimetinib, a MEK inhibitor, and encorafenib, a BRAF inhibitor, in patients with BRAF-mutant advanced, unresectable or metastatic melanoma.

June 01, 2017

Vol.40 No.05

Clinical

Gene-based blood tests identify more skin cancers

Genetic testing of tumor and blood fluid samples from people with and without one of the most aggressive forms of skin cancer has shown that two new blood tests can reliably detect previously unidentifiable forms of the disease.

May 01, 2017

Vol.40 No.04

PD-1 antibody cemiplimab demonstrates 46.3% ORR in advanced cutaneous squamous cell carcinoma

YOU MAY BE INTERESTED IN

FDA clears the way for multi-center investigator-initiated study of Alpha DaRT in immunocompromised patients with recurrent cSCC

Annual Report to the Nation: Declines in lung cancer, melanoma death rates drive overall cancer mortality drop

Cleveland Clinic study: timing of melanoma diagnosis, treatment critical to survival

Delaying lymph node biopsy after diagnosis doesn’t affect survival

Part 2 of phase III study of binimetinib and encorafenib produces positive top-line result

Gene-based blood tests identify more skin cancers

Renew today!

Subscriber content

Never miss an issue!

Login